---
title: Improve movement and speech function
nct_id: NCT07568067
phase: NA
status: RECRUITING
sponsor: Ke Dong, MD
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07568067"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07568067"
last_fetched: "2026-05-10T14:04:06.216Z"
source: "Parkinson's Pathways (curated)"
---
# Improve movement and speech function

**Goal (in five words):** Improve movement and speech function

**Official Title:** A Single-Center, Double-Blind Randomized Controlled Trial of Accelerated Temporal Interference Stimulation Applied to Bilateral Subthalamic Nucleus for Improving Motor and Vocal Functions in Patients With Parkinson's Disease Or Secondary Parkinson's Syndrome

**Trial ID:** [NCT07568067](https://clinicaltrials.gov/study/NCT07568067)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Ke Dong, MD
- **Target Enrollment:** 60 participants
- **Start Date:** 2026-01-05
- **Completion Date:** 2026-08-30
- **Conditions:** Parkinson Disease, Parkinson Disease, Secondary
- **Interventions:** Temporal Interference Stimulation, Temporal Interference Stimulation
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to improve motor symptoms like slowness and tremor, plus vocal problems, by targeting the subthalamic nucleus, a deep brain area that contributes to movement and speech issues in Parkinson's and secondary parkinsonism. The approach uses accelerated temporal interference stimulation, a noninvasive electrical technique that mixes two high-frequency currents to produce a low-frequency effect deep in the brain, modulating neuronal firing in the subthalamic nucleus much like deep brain stimulation but without surgery, and it is intended to complement usual meds such as levodopa rather than replace them. The trial seeks about 60 adults with mild to mid-stage disease, Hoehn and Yahr stage 1.5 to 3, who can walk independently, have no cognitive impairment or prior DBS, can undergo MRI, and are generally under 80 years old.

## Eligibility

- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Confirmed diagnosis of idiopathic Parkinson's disease or secondary parkinson's syndrome ; Hoehn-Yahr stage 1.5-3.
2. Ability to walk independently.
3. Ability to follow instructions, with no cognitive impairment.
4. Patient and their family agree to cooperate with treatment and provide written informed consent.

Exclusion Criteria:

1. Claustrophobia or presence of metallic implants precluding MRI examination and evaluation.
2. Severe dysfunction of vital organs including heart, lung, liver, kidney, etc.
3. Complicated with other neurological diseases such as cerebral infarction.
4. Presence of mental illness, severe depression, anxiety, etc., which may affect the accuracy of study results.
5. History of deep brain stimulation (DBS) surgery.
6. Patients unable or unwilling to cooperate with scale assessments.
7. Aged over 80 years old.
```

## Locations (1)

- Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China _(23.1167, 113.2500)_
  - Hanjun Liu — (CONTACT) — +86 15920175118 — lhanjun@mail.sysu.edu.cn

## Central Contacts

- Zi Dan — (CONTACT) — +86 18922465578 — zidan@mail2.sysu.edu.cn
- Liu Hanjun — (CONTACT) — +86 15920175118 — lhanjun@mail.sysu.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07568067*  
*HTML version: https://parkinsonspathways.com/trial/NCT07568067*  
*Source data: https://clinicaltrials.gov/study/NCT07568067*